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INTRODUCTION  
Attention-deficit/hyperactivity disorder (ADHD) is a common disorder of childhood that, for 
many, persists into adulthood [1]. The disorder is characterized by core symptoms of inattention, 
hyperactivity and/or impulsivity defined in DSM-5 [2] and ICD-10 [3]. Those diagnosed with the 
disorder display impairments in their personal and social functioning (e.g. educational 
attainment, occupational difficulties and relationship problems) [4].  
 
ADHD may be lifelong disorder that has a profound effect on an individual’s quality of life. 
Biederman et al. [5] conducted a 16-year follow-up of 140 boys with ADHD into their thirties and 
compared them with 120 boys without ADHD of a similar age. They found that the ADHD cohort 
had greater impairment in social functioning and daily living. In particular they had greater family 
conflict, dependence on parents for financial support and lower socioeconomic status. The risk 
of impaired functional outcomes seems to be considerably greater for young people with ADHD 
who do not receive treatment. Analysis of data derived from 333 studies, Shaw et al. [6] 
reported that, compared to people without ADHD, 74% of functional outcomes were worse for 
people with untreated ADHD. However with treatment, 72% of functional outcomes improve 
over the longer term. Domains of self-esteem, social function, academic performance and 
antisocial behaviour may respond particularly well to multi-modal treatments that combine both 
pharmacological and non-pharmacological modalities [4].  
 
A range of intervention strategies is available to treat children and adults with ADHD, including 
psychological and pharmacological interventions. International guidelines recommend a 
multimodal treatment approach comprising both pharmacological and psychological 
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interventions [7] and there is empirical support for a larger treatment effect for functional 
outcomes when using a combined approach over the longer term [4]. Psychological treatments 
in adults have generally been based on cognitive behavioural therapy (CBT) [8]. Group 
interventions are attractive for clinical delivery as they are cost effective as well as 
demonstrating medium to large treatment effects for the reduction of ADHD symptoms in 
randomised control trials of medicated ADHD patients [9-15]. However most studies typically 
focus on clinical outcomes rather than functional outcomes as primary measures of success, yet 
the latter are important markers of treatment efficacy due to their translational value, i.e. 
because they often relate to functional activities of daily living.  
 
Young and Gudjonsson [16] demonstrated that functional impairments associated with 
neuropsychological test scores, clinical symptoms of anxiety and depression, and psychosocial 
performance are all significantly related to underlying ADHD symptoms but, for some 
individuals, these impairments improve with remission of symptoms. However for others, 
residual problems will persist with patients seeking psychiatric help in adulthood. Gudjonsson et 
al. [17] investigated the relationship between satisfaction with life, ADHD symptoms, and 
associated functional problems measured by the RATE-S (emotional, social and antisocial) among 
young people in the community. ADHD symptoms and associated problems were significantly 
related to less satisfaction with life. Poor social functioning was the single best predictor of 
dissatisfaction with life in males, whereas in females it was poor emotional control. The study 
shows that even in samples where only mild ADHD symptoms were identified, satisfaction with 
life is adversely affected. The Total RATE-S scale was overall the best predictor of satisfaction 
with life.  
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A study conducted by Emilsson et al. [12] reported significant and large treatment effects at 
three month follow up for functional outcomes (assessed by the RATE-S Scales) for each of its 
four subscales (ADHD symptoms, emotional control, antisocial behaviour and social functioning) 
and the total score. However, their study only involved 54 participants, 27 in each group, and 
there was a substantial amount of missing data at the end of treatment and at three-month 
follow-up for both the CBT/MED and TAU/MED groups which may have led to a biased estimate 
of the treatment effect. To reduce possible bias, White et al. [18] recommends analysing all the 
observed outcome data via the maximum likelihood method under missing data random (MAR) 
assumption. This requires the inclusion of any relevant predictors of missing data in the analysis 
model.  
 
The present study aimed to investigate functional outcomes of a multimodal treatment provided 
to adults with ADHD who were receiving medication and were randomised to receive CBT/MED 
or treatment as usual (TAU/MED). We have previously reported clinical outcomes [15] and in this 
study we report functional outcomes using the RATE-S Scales [19] which were developed to 
assess attention, social functioning, emotional control and antisocial behaviour. Outcomes were 
assessed post group and at three-month follow-up. The RATE-S Total composite scale is 
associated with satisfaction [17]. We performed an intention-to treat analysis using a linear 
mixed model and analysed for three possible predictors of missing data: gender, age, and 
antisocial personality traits. Thus we analysed the effects of treatment over time (i.e. end of 
treatment versus at three-month follow-up) as well as overall group differences in the outcome 
measures whilst controlling for possible group imbalances caused by missing data.  
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It was hypothesised that the CBT/MED group would show significantly greater functional 
improvement compared with the TAU/MED group (after adjusting for missing data and possible 
confounders) in the RATE-S Total composite scale and across each of the four RATES scales 
(ADHD symptoms, emotional control, antisocial behaviour and social functioning).  Second, 
treatment gains were expected to be maintained at three-month follow-up. Third, it was 
hypothesised that functional outcomes on the RATE-S would correlate with independent 
evaluator ratings of the Clinical Global Impression assessment of illness severity.  
 
METHOD 
Trial Design  
This study has been described in detail in our previous study reporting clinical outcomes [15]. 
Briefly, a parallel-group RCT was conducted at an ADHD outpatient setting within the Mental 
Health Services at Landspitali – The National University Hospital of Iceland. All participants 
meeting inclusion criteria were independently and individually randomly allocated (1:1) to 
receive the R&R2ADHD programme (CBT/MED) or treatment as usual (TAU/MED). Assessments 
occurred at three time points: baseline, end of treatment and three months after treatment. The 
study was registered with the international clinical trials registry (ACTRN12611000533998).  
 
Participants  
Participants were outpatients at the Mental Health Services at the Landspitali University 
Hospital, referrals from private practitioners, or self-referrals from an advertisement placed with 
a national ADHD support group (Icelandic ADHD Association). Participants were over 18 years of 
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age, had a current ADHD diagnosis and reported they had remained stable on prescribed ADHD 
medication for at least one month. It was requested that the participants kept their medication 
dosages unchanged during the study. Exclusion criteria included severe mental illness (i.e. 
psychotic disorders, bipolar disorder), active suicidal ideation, severe eating disorder, history of 
drug abuse and general intellectual impairment as without modification the treatment 
programme would not be suitable for these patient groups. Exclusion criteria were evaluated 
from a review of the patient’s medical record and a baseline assessment by an experienced 
mental health practitioner (see baseline assessments section).  
 
Figure 1  
 
187 patients were referred and out of those 95 (51%) participated in the study. Figure 1 provides 
the reasons for non-participation. Eleven participants were excluded because at the intake 
interview they did not meet DSM-IV diagnostic; 62 (65.3%) of the participants were female 
(mean age= 35.00, SD=11.81) and 33 (34.7%) were male (mean age= 35.45, SD=11.62).  
 
Table 1 gives the demographic and clinical characteristics of the study sample. Psychiatrists 
prescribed medication at baseline; 79 (83.2%) were prescribed methylphenidate and 16 (16.8%) 
atomoxetine. Five participants were also taking bupropion. In addition 63 (66.3%) participants 
were taking other prescribed medications including antidepressants, benzodiazepines, insulin 
and ibuprofen.  
 
In addition to ADHD, participants reported comorbid depression (63.2%), anxiety (36.8%), and 
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history of drug/alcohol abuse (15.8%). Seven participants (7.4%) reported that they had been 
diagnosed with a personality disorder and four (4.2%) with Asperger´s Syndrome in childhood. 
Four (4.2%) reported having posttraumatic stress disorder (PTSD) and two (2.1%) with a history 
of eating disorder.  
Table 1  
 
Interventions  
R&R2ADHD is a CBT intervention programme developed for youth and adults with ADHD [20]. It 
is a revised version of the 35-session Reasoning & Rehabilitation prosocial competence training 
programme which has a strong evidence base [21]. It was revised to be a shorter and more 
relevant intervention for individuals presenting with symptoms associated with ADHD. The 
revision, R&R2ADHD, is a structured, manualised programme consisting of fifteen 90-minute 
sessions (excluding a mid-session break) five treatment modules: (a) neurocognitive, e.g. 
learning strategies to improve attentional control, memory, impulse control, and planning; (b) 
problem solving, e.g. developing skilled thinking, problem identification, consequential thinking, 
managing conflict, and making choices; (c) emotional control, e.g. managing feelings of anger 
and anxiety; (d) prosocial skills, e.g. recognition of the thoughts and feeling of others, empathy, 
negotiation skills, and conflict resolution; and (e) critical reasoning, e.g. evaluating options and 
effective behavioural skills. R&R2ADHD is a group treatment supplemented by one-to-one 
meetings with a mentor. In the present study the group sessions were delivered twice per week 
(i.e. with a total duration of 8 weeks). The mentors met with the participants between each 
group session in order to support participants to transfer skills learned in the group into their 
daily lives. Programme integrity was ensured by regular supervision from the programme author 
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(SY). Furthermore group sessions were delivered according to the manual by experienced CBT 
therapists who had received training and accreditation to deliver the programme. The mentoring 
sessions were provided by psychology students who also received training, supervision and 
written guidance.  
Treatment as usual was classified as receiving usual treatment, which included both 
pharmacological and non-pharmacological treatments. All participants received ADHD 
medication but non-pharmacological interventions were not systematically recorded.  
 
Measures  
Baseline assessments  
All of those referrals who could be contacted and who consented to participate in the study 
were interviewed by an experienced mental health practitioner prior to randomization to 
ascertain clinical diagnosis according to DSM-IV criteria using the MINI International 
Neuropsychiatric Interview [22]. In addition, the 54-item Gough Socialization Scale [23] was used 
to measure antisocial personality (ASP) traits. ASP traits have been commonly found in 
outpatients diagnosed with ADHD [24] and have been associated with failure to attend follow-up 
appointments after treatment and hence may relate to missing follow-up data [25]. Socio-
demographic data and medical information from a review of clinical records were obtained (see 
Table 1). IQ scores were not systematically recorded in the clinical records but individuals were 
excluded if reference was made to general intellectual impairment. In addition, a battery of 
measures that were completed by either self-report or by the independent evaluator were 
administered. Those relating to the present study are:  
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1. The RATE-S [19] is a revision of the YAQ-S scale [26] representing the 8 items with the highest 
factor loading from each of the four YAQ-S subscales. It has 32 self-reported items relating to 
functioning and behaviour in the past month. It consists of four subscales: (1) ADHD Symptoms 
(i.e., items relating to attentional difficulties, impulsiveness, and disorganization), (2) Emotional 
Control (i.e., items relating to emotional volatility and include worries, anxieties, depressed 
mood, anger, loss of temper, and poor self-esteem), (3) Antisocial Behaviour (i.e., involvement in 
a range of delinquent behaviours’ such as fighting, theft, damage to property, vandalism, 
reckless behaviour, verbal threats to others, and being arrested and questioned by police), and 
(4) Social Functioning (i.e., items focus on social participation and confidence in social activities). 
Behaviours during the previous month are rated on an 8-point scale, ranging from “not at all” to 
“most of the time”. All scales have shown good internal consistency, as measured by Cronbach’s 
alpha (i.e., exceeding 0.80 both for people with ADHD and normal controls). The scales also 
demonstrate a good discrimination between ADHD patients and clinical controls [26] and a good 
construct validity, both for patients and controls [24]. In the Icelandic translation of the RATE-S 
scale, the measure has demonstrated good reliability and validity [17, 27].  
 
2. Clinical Global Impression [28] consists of a single question observer rating of severity of 
illness on a 7 point scale. It focuses on judgment regarding impairment in functioning, symptom 
severity and distress or coping and is supported by examples of these factors. Clinicians who 
were blind to treatment condition completed the CGI, which has been widely used in treatment 
evaluation studies and found to correlate with ADHD-severity measured by the adult ADHD 
investigator symptom rating scale [29].  
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Procedure  
A battery of self-rated and clinician-rated evaluations (the latter being blind to treatment 
allocation) was completed at the three time points (baseline, post-treatment and at three-
month follow-up). Participants were randomized to either the CBT/MED or TAU/MED condition 
by a psychiatrist at Landspitali University Hospital, who was not involved in the study. The 
psychiatrist did not posses information about the participants and had received numbers that 
were pre-assigned to the participants. Block randomization was performed at the time of each 
study phase by using equal block sizes. The researchers only received the final randomization 
numbers to protect the concealment of the allocation as proposed in various studies [30, 31]. 
The R&R2ADHD programme was delivered twice per week by experienced CBT therapists who 
had received training to deliver the programme. Group participants met their mentor for at least 
30 minutes between group sessions. Mentors had attended a training session to fulfil this role, 
which involved an introduction to the programme and the mentoring role. In addition mentors 
had a manual that guided them through topics to be discussed within the mentoring session. 
They were provided with supervision once a fortnight from the lead group therapist. There were 
a total of five R&R2ADHD treatment groups. Participants in the TAU/MED condition received 
pharmacological intervention and some non-pharmacological interventions but these were not 
systematically provided or recorded.   
 
Statistical analyses  
The statistical analysis first involved applying a logistic regression model to identify factors (i.e. 
age, gender, and antisocial personality traits) that might predict the probability of missing data. 
Only age was significantly associated with the probability of dropouts (i.e. younger participants 
11 
 
more often failed to attend the assessment interviews with the independent raters (CGI, Z=-2.35, 
p=0.019).  
 
An intention-to-treat analysis (i.e. individuals analysed in the group to which they were 
randomized to) of available outcome data was subsequently performed to estimate the effect of 
offering the treatment using a linear mixed model whilst controlling for age. The random 
component of the mixed model included random intercept term for participant identifier to take 
account of between participant variability and the correlation between the repeated measures. 
Within the fixed part of the model, the treatment effect was adjusted for time (i.e. a binary 
indicator of whether an outcome measure corresponds to follow-up or end of treatment) and 
the baseline measures of the respective outcome in all models. We also tested condition by time 
interactions, but none were found statistically significant and therefore were excluded from the 
model.  
 
There was minimal amount of missing data at baseline, but there was a substantial proportion 
(i.e. 37% and 48% for the RATE-S and CGI, respectively) of missing data in the completion of the 
outcome measures due to study dropouts. The dropout rate was similar for CBT/MED and 
TAU/MED groups (see Figure 1) with Chi-square tests showing no significant differences between 
groups.  
 
Two approaches are typically recommended for dealing with the risk of potential bias due to 
missing data: the multiple imputation and complete case analysis via maximum likelihood. Since 
missing data only occurred in the outcome variables the complete case analysis via maximum 
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likelihood was the most appropriate method. We therefore adopted the complete case analysis 
approach under a missing at random (MAR) assumption. Covariates predicting missingness were 
identified using a logistic regression analysis and an analysis of all observed outcome data was 
performed using linear mixed model via maximum likelihood method controlling for predictors 
of missing data, which should produce unbiased estimates under MAR assumption [18].  
 
Adjusted effect sizes, using Cohen’s d, were obtained by calculating the residuals from the  
respective linear mixed model with the condition term excluded, and then calculating the 
standardised mean difference of the adjusted outcome (residuals) between groups. This 
calculation was conducted using the user contributed Stata module COHEND [32], which adjusts 
for uneven group sizes. Table 1 provides descriptive characteristics of the demographic and 
clinical sample data as well as the outcome measures presented in the form of means and 
standard deviations. Differences between CBT/MED and TAU/MED condition at baseline, 
independent sample t-tests were performed and χ²-tests were used to analyse categories and 
categorical data, respectively.  
No significant differences were found between the CBT/MED and the TAU/MED groups in the 
demographic background data.  
 
Table 1  
 
RESULTS  
Baseline characteristics  
Table 2 show that there were no significant differences between the CBT/MED and the 
TAU/MED groups in the baseline outcome measures regarding the RATE-S and CGI.  
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Table 2  
 
Outcomes  
Table 3 provides an output from the linear mixed model analyses for the RATE-S. Each row 
shows the coefficient of the treatment indicator (0=TAU/MED, 1=CBT/MED) and the relevant 
inferential statistics of the named outcome variable. All models included a random intercept 
term for subject identification and controlled for age of participants, time of outcome (indicator 
of whether the measurement corresponds to end of treatment or follow-up or end of 
treatment), and the baseline measurement differences of each respective outcome variable. 
Estimates are provided of the adjusted overall mean differences (i.e. combing the scores from 
end of treatment and at three-month follow-up between the CBT/MED and TAU/MED groups 
and the corresponding p-values).  
 
There was a significant main effect for all the RATE-S outcomes, suggesting that the CBT group 
had significantly reduced scores compared to the TAU group at end of treatment. Significant 
differences emerged between groups on all the outcome variables with low (Emotional Control 
and Social Functioning) to medium (Total, ADHD Symptoms, Antisocial Behaviour) effect sizes.  
 
Table 3  
 
There was an overall effect of time (end of treatment versus three-month follow-up) adjusted 
for baseline, group and age, for the Emotional Control scale (Z=-2.01, p=0.04, d = 0.32) and the 
Total scale (Z=-2.19, p=0.028, d = 0.54) showing steady improvement over time in the treatment 
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group.  
 
Table 4 shows that there was a significant correlation between the CGI and RATE-S scores at 
baseline, end of treatment and follow-up, mostly with medium to large effects sizes, with two 
exceptions. The Antisocial scale did not correlate significantly with the CGI scale at the end of 
treatment; nor did Social Functioning at follow-up. The correlations were overall most marked 
for the RATE-S Total scale.  
 
Table 4  
 
DISCUSSION  
Arnold et al. [4] emphasise the importance of investigating improvements in the personal and 
social functioning of people treated for ADHD rather than merely focusing on changes in their 
core symptoms. This was the primary aim of the current study. Investigating the functional 
outcomes (ADHD Symptoms, Social Functioning, Emotional Control, Antisocial Behaviour and a 
general composite Total Scale) of a multimodal treatment provided to adults with ADHD 
(R&R2ADHD) who were receiving medication and randomised to receive CBT/MED or treatment 
as usual. The study employed a linear mixed model to control for confounders associated with 
missing data, between subject variability and the correlation between the measures over time. 
The treatment effect in the model was adjusted for time, which allowed us to investigate 
whether or not the treatment effectiveness noted at the end of treatment was maintained or 
improved at three-month follow-up, in addition to investigating the overall effect of the end of 
treatment and three-month follow-up combined.  
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As hypothesized, the CBT/MED group showed an overall significant treatment effect (i.e. the 
RATE-S Total composite scale) with a medium effect size. In addition, there were significant 
effects on all four subscales, with medium effect sizes being noted for the ADHD and Antisocial 
scales. Hence the perception of group participants was that they had experienced significantly 
greater functional improvement at the end of the group treatment compared with those 
receiving TAU. Importantly, the findings show that there were both significant group effects and 
time effects with the treatment effect being maintained at three-month follow-up for all scales 
except for Emotional Control and Total composite scales which continued to improve after the 
group had ended. This supports previous findings that anxiety, depression and quality of life also 
continue to improve over time following group completion [15] and extends those findings by 
showing that clinical improvements translate into daily activities and behaviours. Future 
research should include functional outcomes that are assessed at follow-up as well as post-
treatment in order to capture some benefits of treatment that may present later due to the 
apparent time lag for some outcomes.  
 
The hypothesis that functional outcomes on the RATE-S would correlate with independent 
evaluator ratings of the CGI assessment of illness severity was supported at baseline, end of 
treatment and at follow-up with the exception of the Social Function scale at follow-up. Large 
effect size correlations were found between the CGI and the RATE-S Total scale at the end of 
treatment and at follow-up. This demonstrates an important link between illness severity and 
functional impairment. One explanation for the lack of significance for the Social Function scale 
at follow-up may be that the CGI relates most well to functional behaviours that are associated 
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with clinical syndromes, such as ADHD, emotional instability and behavioural control.  
 
A strength of the study is the randomised methodology and a reasonable sample size. 
Additionally the independent raters of the CGI were blind to treatment condition. The study’s 
main limitation is the high dropout rate, which left us with a substantially reduced sample at 
follow up. Just over half of the sample completed the programme.  High attrition has also been 
reported in other studies [33, 34].The TAU/MED group did not receive any active non-
medication control intervention as part of the research protocol, which may also have inflated 
the treatment effects in the CBT/MED group. Nevertheless, all the participants were receiving 
medication for ADHD, which in itself should be considered to be an active control. The patients 
had all been clinically diagnosed with ADHD but from different centers. Participants were 
assessed by the researchers on the MINI International Neuropsychiatric Interview at baseline, 
but did not receive any further ADHD clinical assessment. Dosage and treatment compliance was 
not systematically recorded, although stability on medication was self-reported. 
It is notable that participants presented with a high rate of ADHD symptoms – their mean 
symptom ratings were over 10 points higher than those obtained in the RATE validation studies 
(19). This suggests that participants were a severely impaired group who may have been poor 
responders to medication. Hence, the combination of the R&R2ADHD program with medication 
significantly improves the treatment effect. 
To conclude, the present findings complement our previous findings and together demonstrate 
that those individuals receiving the multimodal treatment of ADHD medication plus R&R2ADHD 
will experience a significant reduction in ADHD and comorbid symptoms and that this 
improvement translates into everyday function. The key mechanism associated with improved 
functional outcomes is likely to be behavioural control.  
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Figure 1: Flow chart of patient participation   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
187 referred to the study 
 92 Excluded following clinical assessments (49%) 
 30 declined participation (33%) 
 18 could not be contacted (20%) 
 16 no longer on medication (17%) 
 11 did not receive an ADHD diagnosis (12%) 
 8 active substance misuses (9%) 
 7 did not attend assessment (8%) 
  2 under the age of 18 (2%) 
 
 
End of treatment 
35 Completed either self-reports or independent 
evaluations (73%): 
33 Completed independent evaluations (69%) 
34 Completed self-reports (71%) 
Baseline 
48 Intake interviews: 
47 Completed independent evaluations (98%) 
46 Completed self-reports (96%) 
48 Allocated to CBT/MED condition 
 
Baseline 
47 Intake interviews: 
45 Completed independent evaluations(96%) 
46 Completed self-reports (98%) 
47 Allocated to TAU/MED condition 
 
End of treatment 
39 Completed either self-reports or independent 
evaluations (83%): 
34Completed independent evaluations (72%) 
35 Completedself-reports (74%) 
Follow-up 
27 Completed either self-reports or independent 
evaluations measures (56%): 
21 Completed independent evaluations (44%) 
25 Completed self-reports (52%) 
Follow-up 
32 Completed either self-reports orindependent 
evaluations (68%): 
27 Completed independent evaluations (57%) 
32 Completed self-reports (68%) 
 
95 Randomized (51%) 
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